Valo Therapeutics Funding Round

3/10/2025

Venture Equity

$19,000,000

Undisclosed

The company intends to use the funds to expand and complete the Phase 1B clinical study of its lead tumour antigen-coated oncolytic virus candidate. Part of the investment round will be invested in Italy and allocated to the activities of the newly created Italian operating company, Valo Therapeutics Italy Srl, which will be based in Naples, with the aim of carrying out specific activities in the territory of Southern Italy such as (i) enrolling and treating patients in Southern Italy, (ii) initiating the large scale manufacturing of virus supporting product development up to the commercial phase, and (iii) supporting research activities in Institutions based in Naples and south of Italy.

Private & Independent

Biopharmaceutical

Viikinkaari 6
Helsinki, 00790
FI

Undisclosed

Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.